Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians

Shuhaili, Meor Fairuz Rizal Meor Anuar; Samsudin, Intan Nureslyna; Stanslas, Johnson; Hasan, Shariful; Thambiah, Subashini C.

doi:10.5812/ijem.43319

Cited by 29 publications

(23 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the end of 12 weeks, target values were achieved with rosuvastatin in 76% of patients, with atorvastatin in 58%, and with simvastatin in 53%. 16 It is known that atorvastatin 20 mg is pharmacokinetically the same as rosuvastatin 10 mg. 17 In the present study, LDL cholesterol level decreased with both statins at the end of the 12th month versus baseline, but no statistically significant difference was found between the groups.…”

Section: Discussioncontrasting

confidence: 62%

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia

Demir

Doğru

Ede

et al. 2018

CVJA

View full text Add to dashboard Cite

SummaryIntroductionStatins can reduce cardiovascular events and improve endothelial function. However, differences in the effect of statins on endothelial dysfunction have not been researched sufficiently. Here, we aimed to compare the effects of atorvastatin versus rosuvastatin on endothelial function via flow–mediated and endothelial–independent dilation. MethodsHyperlipidaemic subjects on treatment with statins for one year (either 20 mg/day atorvastatin or 10 mg/day rosuvastatin) were enrolled in the study. In accordance with the literature, flow–mediated dilation (FMD) and nitrate–mediated endothelium–independent dilation (EID) were measured by ultrasonography on the right brachial artery of each subject. Baseline and final measurements were compared in each group and between the groups.ResultsOne hundred and four subjects (50 atorvastatin and 54 rosuvastatin users) were enrolled in the study. Fifty–eight subjects were female. The groups were statistically similar in terms of age and body mass index, and haemoglobin, creatinine, total cholesterol, triglyceride, high–density lipoprotein and low–density lipoprotein cholesterol levels. In each group, the mean final FMD and EID values were higher compared to their respective baseline values, but the mean changes in FMD and EID were statistically similar in both groups (p = 0.958 for FMD and 0.827 for EID). There was no statistically significant difference between the atorvastatin and rosuvastatin groups in terms of final FMD and EID values (p = 0.122 and 0.115, respectively). ConclusionThis study demonstrated that both one–year atorvastatin and rosuvastatin treatments significantly improved endothelial function, when assessed with FMD and EID and measured by ultrasonography. However, the amount of improvement in endothelial dysfunction was similar in the two treatments.

show abstract

Section: Discussioncontrasting

confidence: 62%

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia

Demir

Doğru

Ede

et al. 2018

CVJA

View full text Add to dashboard Cite

show abstract

“…A counterpoint to this argument would be that the subjects in our STEMI population were more likely to be on oral medications for hyperlipidemia, and it is known that statins exert a pleiotropic anti-inflammatory effect 33 . Statins result in lower TC, LDL-C and TG levels 34 . A study demonstrated the effect of statins on outcome modification in patients with low LDL-C levels.…”

Section: Discussionmentioning

confidence: 99%

The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry

Sia

Zheng

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Lowering low-density lipoprotein (LDL-C) and triglyceride (TG) levels form the cornerstone approach of cardiovascular risk reduction, and a higher high-density lipoprotein (HDL-C) is thought to be protective. However, in acute myocardial infarction (AMI) patients, higher admission LDL-C and TG levels have been shown to be associated with better clinical outcomes-termed the 'lipid paradox'. We studied the relationship between lipid profile obtained within 72 hours of presentation, and all-cause mortality (during hospitalization, at 30-days and 12-months), and rehospitalization for heart failure and nonfatal AMI at 12-months in ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients treated by percutaneous coronary intervention (PCI). We included 11543 STEMI and 8470 NSTEMI patients who underwent PCI in the Singapore Myocardial Infarction Registry between 2008-2015. NSTEMI patients were older (60.3 years vs 57.7 years, p < 0.001) and more likely to be female (22.4% vs 15.0%, p < 0.001). In NSTEMI, a lower LDL-C was paradoxically associated with worse outcomes for death during hospitalization, within 30-days and within 12-months (all p < 0.001), but adjustment eliminated this paradox. In contrast, the paradox for LDL-C persisted for all primary outcomes after adjustment in STEMI. For NSTEMI patients, a lower HDL-C was associated with a higher risk of death during hospitalization but in STEMI patients a lower HDL-C was paradoxically associated with a lower risk of death during hospitalization. For this endpoint, the interaction term for HDL-C and type of MI was significant even after adjustment. An elevated TG level was not protective after adjustment. These observations may be due to differing characteristics and underlying pathophysiological mechanisms in NSTEMI and STEMI.

show abstract

“…These are among the most commonly prescribed medicines worldwide for the prevention of cardiovascular complications and mortality, and studies have suggested that, in addition to decreasing serum lipids, statins also show pleiotropic effects that are not directly associated with cholesterol synthesis, such as improving endothelial dysfunction, reducing inflammatory response, stabilizing atherosclerotic plaque, and decreasing thrombogenic response . Compared with hydrophilic statins (eg, pravastatin), lipophilic statins (egatorvastatin and simvastatin) can be more widely distributed to the tissues and cells through passive diffusion …”

Section: Introductionmentioning

confidence: 99%

Protective effect of atorvastatin on oxidative stress in streptozotocin‐induced diabetic rats independently their lipid‐lowering effects

Aktay

Gürsoy

Uyumlu

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

In the present study, we investigate the effects of atorvastatin on the lipid profile, oxidative stress, and liver enzyme markers, and its protective activity against diabetic complications, in streptozotocin (STZ)-induced diabetic rats. Fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), and high-density lipoprotein (HDL) levels, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme activities, were measured 7 weeks after the administration of STZ and atorvastatin. Thiobarbituric acid reactive substances (TBARS), non-protein associated sulfhydryl (NP-SH), total sulfhydryl (T-SH), and nitric oxide (NO) levels were measured to evaluate oxidative stress. Atorvastatin was found to inhibit ALT and AST activities and to reduce FBG levels in rats with STZ-induced diabetes. Moreover, atorvastatin treatment significantly reduced lipid peroxidation in kidney, heart, and eye tissues (P < 0.001, for all), and resulted in a significant increase in NP-SH levels in brain tissues (P < 0.001). Total NO and nitrate levels increased significantly after atorvastatin treatment (P < 0.01). Our results revealed that atorvastatin has a protective effect against STZ-induced oxidative damage by reducing TBARS levels and increasing NP-SH levels, has a hepatoprotective effect by decreasing ALT and AST activities. It also shows the antihyperglycemic activity by lowering FBG levels. K E Y W O R D Satorvastatin, diabetes mellitus, lipid peroxidation, liver enzymes, streptozotocin (STZ)

show abstract

Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians

Cited by 29 publications

References 52 publications

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia

The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry

Protective effect of atorvastatin on oxidative stress in streptozotocin‐induced diabetic rats independently their lipid‐lowering effects

Contact Info

Product

Resources

About